P008 Showdowns in Pediatric Dermatology: Current Controversies from the Pediatric Dermatology Research Alliance
DESCRIPTION
The goal of this session is to bring novel but controversial topics in pediatric dermatology to the main stage by bringing together experts from the Pediatric Dermatology Research Alliance (PeDRA)! The target audience are dermatologists, especially those who see pediatric patients. During this session, 3 hot-off-the-press but controversial topics will be presented to the audience as live panel debates with at least one discussant for and one discussant against a particular topic. We will bring together experts in the field on the controversy at hand and through lively discussion, present the most up to date evidence differing opinions.
LEARNING OBJECTIVES
Examine novel and groundbreaking topics in pediatric dermatology and pediatric dermatology research.
Compare and contrast perspectives in controversial topics.
Evaluate and summarize the evidence presented and formulate his or her own opinions.
SCHEDULE
8:45 AM
Discussion
DIRECTORS
Dawn Eichenfield, PhD, MD, FAAD
Anna Cristina Garza-Mayers, MD, PhD, FAAD
Seattle Children's Hospital, University of Washington
SPEAKERS
Alreem Al-Nabti, MD, FAAD
Weill Cornell Medicine
Maria Gnarra Buethe, MD, PhD, FAAD
Rady Children's Hospital Orange County/University of California, Irvine
Karen Chernoff, MD, FAAD
Weill Cornell Medicine
Jinia El Feghaly, MD
University of Rochester, Rochester, NY & American University of Beirut, Beirut, Lebanon
Thy Nhat Huynh, MD, FAAD
Mary Elizabeth Larijani, MD, FAAD
Perelman School of Medicine at the University of Pennsylvania, Children’s Hospital of Philadelphia
DISCLOSURES
Alreem Al-Nabti, MD, FAAD
No financial relationships exist with ineligible companies.
Maria Gnarra Buethe, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Karen Chernoff, MD, FAAD
No financial relationships exist with ineligible companies.
Dawn Eichenfield, PhD, MD, FAAD
Amryt Pharma/ Chiesi Farmaceutici – Consultant(Fees); Apogee Therapeutics – Consultant (1099 relationship)(Fees); Arcutis, Inc. – Consultant (1099 relationship)(Fees); Beiersdorf, Inc. – Consultant (1099 relationship)(Fees), Speaker(Honoraria); Eli Lilly and Company – Advisory Board(Fees), Investigator(Grants/Research Funding); Galderma Laboratories, LP – Speaker(Honoraria); Incyte Corporation – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Janssen Pharmaceuticals, Inc – Investigator(Grants/Research Funding); NobelPharma – Advisory Board(Fees), Speaker(Honoraria); Ortho Dermatologics – Advisory Board(Fees); Palvella Therapeutics – Consultant (1099 relationship)(Fees); Pelthos Therapeutics – Advisory Board(Fees); Sanofi/Regeneron – Speaker(Honoraria); Verrica Pharmaceuticals Inc – Advisory Board(Fees), Speaker(Honoraria);
Jinia El Feghaly, MD
NobelPharma – Consultant (1099 relationship)(Other Financial Benefit); Palvella Therapeutics – Consultant (1099 relationship)(Fees); Song Lab Skincare – Consultant (1099 relationship)(No Compensation Received);
Anna Cristina Garza-Mayers, MD, PhD, FAAD
Incyte – Investigator(No Compensation Received); Sanofi – Investigator(No Compensation Received); Sanofi/Regeneron – Advisory Board(Honoraria);
Thy Nhat Huynh, MD, FAAD
No financial relationships exist with ineligible companies.
Mary Elizabeth Larijani, MD, FAAD
No financial relationships exist with ineligible companies.